Preoperative Serum Hypersensitive-c-Reactive-Protein (Hs-CRP) to Albumin Ratio Predicts Survival in Patients with Luminal B Subtype Breast Cancer
Xiujun Liu,Xiuchun Guo,Zhiqiang Zhang
DOI: https://doi.org/10.2147/OTT.S320111
IF: 4
2021-07-09
OncoTargets and Therapy
Abstract:Xiujun Liu, 1, &ast Xiuchun Guo, 2, &ast Zhiqiang Zhang 1 1 Department of Thyroid and Breast Surgery, Bayan Nur Hospital, Bayannaoer, 015000, Neimenggu, People's Republic of China; 2 Deparment of Internal Medicine-Oncology, Bayan Nur Hospital, Bayannaoer, 015000, Neimenggu, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhiqiang Zhang Department of Thyroid and Breast Surgery, Bayan Nur Hospital, Bayannaoer, 015000, Neimenggu, People's Republic of China Email Objective: To evaluate the clinical prognostic significance of preoperative serum hypersensitive-c-reactive-protein (Hs-CRP) to albumin ratio (CAR) in patients with luminal B subtype breast cancer. Methods: A total of 199 patients with luminal B subtype breast cancer enrolled in this study were analyzed retrospectively. The optimal cutoff value of CAR was performed by the receiver operating characteristic curve (ROC). The associations between luminal B subtype breast cancer and clinicopathological variables by CAR were performed by chi-square test. Kaplan–Meier and log rank method were used for survival analysis. The independent prognostic factors were determined by univariate and multivariate Cox's proportional hazards regression model. Results: The patients were divided into low CAR group (CAR< 0.044) and high CAR group (CAR≥ 0.044) by ROC. CAR was the independent factor by univariate and multivariate analysis, and the mean DFS and OS in the low CAR group survived longer than those in the high CAR group (p< 0.05). According to the endocrine therapy with aromatase inhibitors, the mean survival time of DFS and OS in the low CAR group was significantly higher than that in the high CAR group (p< 0.05). Moreover, patients with pathological I+II stage survived longer than those with pathological III stage, and the mean survival time of DFS and OS in the low CAR group was significantly higher than that in the high CAR group (p< 0.05). Patients without lymph vessel invasion survived longer than those with lymph vessel invasion (p< 0.05), and the mean survival time of DFS and OS in low the CAR group was significantly higher than that in the high CAR group (p< 0.05). Conclusion: Preoperative CAR was significantly associated with survival and prognosis of breast cancer, and it can be used as a routine prognostic indicator to predict the prognosis of luminal B subtype breast cancer. Keywords: hypersensitive-c-reactive-proteins, Hs-CRP, albumin, ALB, breast cancer, prognosis Breast cancer is a disease with multi-gene involvement, multi-stage pathological changes and development, and long-term effects of many factors. 1 It is the most common malignancy in females, and the incidence and mortality rate are rising rapidly; it is also the leading cause of cancer deaths all over the world. 2 According to the global cancer statistics in 2020, about 19.3 million cases were diagnosed with new cancers, and 10 million cases died; breast cancer has surpassed lung cancer as the most common malignant tumor, with 2.3 million new cases and 680,000 deaths due to breast cancer. 2 According to data from cancer centers in China, there are 270,000 new cases of breast cancer and 70,000 deaths due to breast cancer; and the incidence and mortality rates in cities are higher than in the countryside. 3 Hormone receptor positive breast cancer is the most common type in breast cancer molecular type, accounting for about 70–75%; endocrine therapy is the main adjuvant treatment for this subtype, and can reduce the mortality by 25–30%. 4 Moreover, the luminal B subtype breast cancer mainly includes two types: 1) HER2 positive, ER/PR positive, Ki-67 in any condition; 2) HER2 negative, ER/PR positive, Ki-67 high or PR low expression. 5 Endocrine therapy usually lasts for a long time; however, these patients will appear drug resistant or experience other side effects. Tumor associated inflammatory response (TAIR) has attracted much attention in the occurrence, development and treatment of malignant tumors. 6 , 7 C-reactive protein (CRP) is an acute phase reaction protein synthesized by liver, and plays an important role in the occurrence and development of inflammatory reaction, and acts an inflammatory marker. 8 Nevertheless, hypersensitive-c-reactive protein (Hs-CRP) can be used to detect the low concentration of CRP by hypersensitive detection technology, and is a sen -Abstract Truncated-
oncology,biotechnology & applied microbiology